Why participate?
Know the major stages of the development cycle of an Antibody-Drug Conjugate (ADC). Understand the tools available to modulate ADC activity.
Training Context:
The ADC field is booming, with $100 billion in transactions recorded in 2023. As of March 2024, 13 ADCs were approved exclusively in oncology across 24 therapeutic indications. Worldwide, over 800 products are currently in research and development, with more than 250 in clinical trials.
Welcome of participants, introductions
General discussion, conclusion, and evaluation
Interactive Teaching, Case Studies, Experience Sharing
Business developer, Application engineer, Research engineer, Researcher, Manager from service companies or Biotechnology firms
Good knowledge of antibodies or having completed the training “Fundamentals of therapeutic antibodies”
Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.
There is no rating available because this training session was never carried out.
Registering online or by e-mail is a pre-registration. We will process your request within one week:
Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.
When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.
For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr
